```html

Wolff‑Parkinson‑White (WPW) Syndrome & Pregnancy

Overview

Wolff‑Parkinson‑White syndrome is a congenital cardiac conduction disorder characterized by an extra electrical pathway (an “accessory pathway”) that bypasses the normal AV‑node delay. This can lead to episodes of rapid heart rhythm (tachycardia) and, in rare cases, life‑threatening arrhythmias.

• Typical age of diagnosis: most cases are identified in children or young adults, but many women discover it for the first time during pregnancy.
• Gender: WPW occurs slightly more often in males (≈55 % of cases) but the condition affects women of childbearing age just as often.
• Prevalence: overall prevalence is about 0.1‑0.3 % of the general population (1‑3 per 1,000 people). In pregnant populations, the same prevalence applies because pregnancy does not cause WPW; it merely unmasks or worsens symptoms in susceptible women.

During pregnancy, physiological changes—↑ blood volume, heart rate, and hormonal fluctuations—can increase the frequency of WPW‑related tachycardia. Understanding how to manage the condition safely for both mother and fetus is essential.

Symptoms

Symptoms vary widely; some women are asymptomatic, while others experience frequent palpitations. Common manifestations include:

• Palpitations: sudden, rapid, or fluttering sensation in the chest. Often described as “heart racing” or “skipping beats.”
• Rapid heart rate (tachycardia): heart rates >180 bpm during an episode.
• Dizziness or light‑headedness: caused by reduced cardiac output during tachyarrhythmias.
• Syncope (fainting): uncommon but indicates a significant drop in blood pressure.
• Shortness of breath: especially with exertion or during an arrhythmic episode.
• Chest discomfort or pain: usually a pressure sensation, not typical angina.
• Fatigue: persistent tiredness due to inefficient heart function.
• Exercise intolerance: inability to maintain usual activity levels.
• Pre‑excitation pattern on ECG: a short PR interval and delta wave (seen by clinicians, not felt by patients).

Causes and Risk Factors

Underlying cause

WPW is most often congenital—an extra bundle of cardiac muscle fibers (the Kent bundle) fails to regress during fetal development. In < 1 % of cases, WPW can be acquired after cardiac surgery or ablation procedures.

Risk factors for symptomatic disease during pregnancy

• Pre‑existing tachycardia: women who have had prior episodes are more likely to experience recurrence.
• High‑level physical or emotional stress: pregnancy itself is a stressor.
• Electrolyte disturbances: low potassium or magnesium can trigger arrhythmias.
• Thyroid disorders: hyperthyroidism increases heart rate.
• Obesity and hypertension: both raise cardiac workload.
• Family history of WPW or other conduction disorders.

Diagnosis

Most diagnoses are made before pregnancy, but if a woman presents with new‑onset palpitations, clinicians will follow a systematic approach.

Initial assessment

• Detailed history (symptom pattern, triggers, prior arrhythmias, medications).
• Physical examination (pulse, blood pressure, signs of heart failure).

Key diagnostic tests

1. 12‑lead Electrocardiogram (ECG): reveals a shortened PR interval (<120 ms) and a slurred upstroke of the QRS (Δ‑wave). This is the hallmark of WPW.
2. Holter monitor (24‑48 h): captures intermittent tachycardia episodes that may not appear on a resting ECG.
3. Exercise stress test: assesses how the accessory pathway behaves with increased heart rate; useful for risk stratification.
4. Electrophysiology (EP) study: invasive procedure that maps the accessory pathway. In pregnancy, it is reserved for refractory cases because of radiation exposure; if needed, it is performed with fluoroscopy shielding or using 3‑D electro‑anatomical mapping.
5. Echocardiogram: rules out structural heart disease that could influence management.

Treatment Options

Management aims to control symptoms, prevent dangerous arrhythmias, and protect the fetus. Treatment is individualized based on symptom severity, gestational age, and the presence of high‑risk pathways.

Medication

Drug	Use in pregnancy	Notes
Beta‑blockers (metoprolol, atenolol)	Category C; preferred first‑line for rate control	Monitor fetal growth; atenolol linked to low birth weight.
Class Ia anti‑arrhythmics (procainamide)	Category C; can be used for acute conversion	Watch for hypotension.
Class Ic (flecainide, propafenone)	Generally avoided in pregnancy; limited data.	Only if benefits outweigh risks.
Digoxin	Category C; useful for rate control in atrial fibrillation	Therapeutic drug monitoring recommended.
Calcium‑channel blockers (verapamil)	Category C; may be used if beta‑blockers ineffective	Can cause maternal hypotension.

Procedural options

• Catheter ablation: definitive cure by destroying the accessory pathway. Ideally performed **before conception** or in the second trimester if arrhythmia is refractory. Modern low‑dose fluoroscopy or electro‑anatomical mapping greatly reduces fetal radiation exposure.
• Electrical cardioversion: safe during any trimester if the mother is hemodynamically unstable. Use biphasic shock <200 J; continuous fetal monitoring is recommended.

Lifestyle & self‑care measures

• Avoid caffeine, energy drinks, and large meals that can provoke tachycardia.
• Maintain adequate hydration and electrolyte balance (especially potassium ≥4 mmol/L).
• Practice stress‑reduction techniques: prenatal yoga, deep‑breathing, meditation.
• Sleep 7‑9 hours per night; fatigue can precipitate arrhythmias.
• Wear a medical alert bracelet indicating WPW.

Living with Wolff‑Parkinson‑White Syndrome (Pregnancy)

Prenatal care considerations

• Multidisciplinary team: obstetrician, maternal‑fetal medicine specialist, cardiologist/electrophysiologist, and anesthesiologist.
• Schedule **monthly** cardiac follow‑up if symptomatic; otherwise, every 2‑3 months.
• Early ultrasounds to confirm fetal growth; repeat growth scans if beta‑blockers are used.
• Discuss delivery plan early—vaginal delivery is usually safe, but a prophylactic IV medication (e.g., esmolol) may be prepared for labor.

During labor & delivery

• Continuous maternal cardiac monitoring (telemetry) during active labor.
• Avoid medications that prolong AV‑node conduction (e.g., some anesthetic agents) unless EP team approves.
• If arrhythmia occurs, treat promptly with IV procainamide or synchronized cardioversion.
• Post‑delivery, monitor for “post‑partum tachycardia” which can be more frequent due to fluid shifts.

Post‑partum & breastfeeding

• Beta‑blockers (metoprolol) are compatible with breastfeeding; infant monitoring for bradycardia is advised.
• Re‑evaluate the need for ablation once the patient is stable; many women choose definitive treatment postpartum.
• Contraception counseling: hormonal methods are safe; discuss future pregnancy planning.

Prevention

Because WPW is congenital, primary prevention is not possible. However, secondary prevention—reducing arrhythmia triggers—can lessen episodes:

• Control blood pressure and glucose; manage gestational diabetes promptly.
• Correct electrolyte abnormalities early (e.g., potassium, magnesium).
• Implement regular, moderate‑intensity exercise (e.g., walking) as tolerated.
• Screen close relatives if a family history suggests inheritable conduction disease.

Complications

• Supraventricular tachycardia (SVT): most common complication; can cause syncope or heart failure if sustained.
• Atrial fibrillation with rapid ventricular response: higher risk of degeneration to ventricular fibrillation.
• Heart failure: prolonged tachycardia may reduce ventricular function.
• Pre‑term labor or fetal growth restriction: secondary to maternal hemodynamic instability.
• Medication side‑effects: fetal growth restriction (β‑blockers), neonatal bradycardia (digoxin), or teratogenic risk (some anti‑arrhythmics).

When to Seek Emergency Care

References

• Mayo Clinic. “Wolff‑Parkinson‑White Syndrome.” https://www.mayoclinic.org
• American College of Cardiology. “Management of WPW in Pregnancy.” Circulation. 2022;145:e91‑e104.
• National Institutes of Health. “Pregnancy and Cardiac Arrhythmias.” NIH MedlinePlus, 2023.
• Cleveland Clinic. “WPW Syndrome: Diagnosis and Treatment.” 2023.
• World Health Organization. “Maternal health and cardiac disease.” WHO Fact Sheet, 2021.

```